Lexicon Pharmaceuticals Commences Underwritten Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Lexicon Pharmaceuticals announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock. Lexicon currently intends to use the net proceeds that it will receive from the proposed offering (i) to fund the continued research and development of its drug candidates and (ii) for working capital and other general corporate purposes. Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LXRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LXRX
Wall Street analysts forecast LXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LXRX is 3.97 USD with a low forecast of 1.90 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.440
Low
1.90
Averages
3.97
High
6.00
Current: 1.440
Low
1.90
Averages
3.97
High
6.00
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lexicon Pharmaceuticals Prices Public Offering at $1.30 per Share
- Public Offering Pricing: Lexicon Pharmaceuticals has priced its public offering at $1.30 per share for 32 million shares, aiming to raise $41.6 million, which reflects the company's proactive financing strategy to support its R&D initiatives.
- Additional Share Option: The firm has granted underwriters a 30-day option to purchase up to 4.8 million additional shares at the public offering price, providing flexibility that could enhance fundraising capabilities and support future business expansion.
- Concurrent Private Placement: Alongside the public offering, Lexicon plans to raise approximately $41.1 million through a private placement, selling 22.4 million common shares and 184,366 shares of convertible preferred stock, indicating a strategic approach to diversify its funding sources.
- Clear Use of Proceeds: Lexicon intends to utilize the net proceeds for the continued research and development of its drug candidates and for general corporate purposes, demonstrating the company's confidence in future growth and its ongoing commitment to investment in the biopharmaceutical sector.
Continue Reading
Lexicon Pharmaceuticals Prices Public Offering at $1.30 per Share
- Public Offering Size: Lexicon Pharmaceuticals has priced its public offering at $1.30 per share for 32 million shares, expecting gross proceeds of $41.6 million, which will significantly bolster funding for its research and development initiatives.
- Concurrent Private Placement: The company is also set to sell 22.4 million shares of common stock and 184,366 shares of Series B Convertible Preferred Stock in a concurrent private placement, anticipated to generate approximately $41.1 million, thereby enhancing its capital structure.
- Strategic Use of Proceeds: Lexicon intends to utilize the net proceeds from both the public offering and private placement for drug development and general corporate purposes, indicating a strong commitment to future product development and responsiveness to market demands.
- Underwriter Participation: With Jefferies and Piper Sandler acting as joint book-running managers for the public offering, this involvement reflects market confidence in Lexicon while providing the company with essential capital market expertise.
Continue Reading